Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N, Desmeules P, Litvak AM, Pietanza MC, Santos-Zabala ML, Ni A, Montecalvo J, Chang JC, Beras A, Preeshagul IR, Sabari JK, Rudin CM, Ladanyi M, Klimstra DS, Travis WD, Lai WC. Rekhtman N, et al. Among authors: rudin cm. Mod Pathol. 2019 Jul;32(8):1106-1122. doi: 10.1038/s41379-019-0248-2. Epub 2019 Mar 28. Mod Pathol. 2019. PMID: 30923345 Free PMC article.
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. Paik PK, et al. Among authors: rudin cm. Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-85. doi: 10.1007/s00280-010-1265-5. Epub 2010 Feb 18. Cancer Chemother Pharmacol. 2010. PMID: 20165849 Free PMC article. Clinical Trial.
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM. Paik PK, et al. Among authors: rudin cm. Lung Cancer. 2011 Dec;74(3):481-5. doi: 10.1016/j.lungcan.2011.05.005. Epub 2011 May 26. Lung Cancer. 2011. PMID: 21620511 Free PMC article. Clinical Trial.
Small cell lung cancer: where do we go from here?
Byers LA, Rudin CM. Byers LA, et al. Among authors: rudin cm. Cancer. 2015 Mar 1;121(5):664-72. doi: 10.1002/cncr.29098. Epub 2014 Oct 21. Cancer. 2015. PMID: 25336398 Free PMC article. Review.
Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, Jones DR, Adusumilli PS. Ujiie H, et al. Among authors: rudin cm. J Clin Oncol. 2015 Sep 10;33(26):2877-84. doi: 10.1200/JCO.2015.60.9818. Epub 2015 Aug 10. J Clin Oncol. 2015. PMID: 26261257 Free PMC article.
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ. Saunders LR, et al. Among authors: rudin cm. Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. Sci Transl Med. 2015. PMID: 26311731 Free PMC article.
558 results